Skip to main content
Clinical Trials/NCT02981030
NCT02981030
Completed
Phase 4

Acceptability and Feasibility of a Simplified Medical Abortion Service Delivery in Western Ukraine: A Demonstration Study of 800 mcg Buccal Misoprostol Following 200 mg Mifepristone for Abortion up to 70 Days Gestation

Gynuity Health Projects2 sites in 1 country102 target enrollmentNovember 23, 2016

Overview

Phase
Phase 4
Intervention
Mifepristone
Conditions
Abortion, Therapeutic
Sponsor
Gynuity Health Projects
Enrollment
102
Locations
2
Primary Endpoint
Rate of successful abortion
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The study will examine how a simplified outpatient medical abortion procedure using mifepristone and misoprostol, with the option to take mifepristone at a place of woman's choosing, works in Ukraine. The investigators intend to demonstrate the efficacy of oral administration of 200 mg mifepristone and buccal administration of 800 mcg misoprostol with gestations through 70 days, as well as the acceptability of this method.

Registry
clinicaltrials.gov
Start Date
November 23, 2016
End Date
June 30, 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Sponsor
Gynuity Health Projects
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Have an intrauterine pregnancy consistent with gestational age less than 71 days;
  • Be able to understand and willing to sign a consent form;
  • Be eligible for medical abortion according to the clinician's assessment;
  • Be able to return to the clinic and able to contact study staff or emergency medical services, if needed;
  • Be willing to provide an address and/or telephone number for purposes of follow-up;
  • Agree to comply with the study procedures and visit schedule.

Exclusion Criteria

  • Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass;
  • Chronic renal failure;
  • Concurrent long-term corticosteroid therapy;
  • History of allergy to mifepristone, or misoprostol or another prostaglandin;
  • History of hemorrhagic disorders or concurrent anticoagulant therapy;
  • History of inherited porphyrias;
  • Intrauterine device in place (must be removed before mifepristone is administered).

Arms & Interventions

Simplified medical abortion

Women seeking medical abortion will be offered the option self-administering the medications, mifepristone and misoprostol at home.

Intervention: Mifepristone

Simplified medical abortion

Women seeking medical abortion will be offered the option self-administering the medications, mifepristone and misoprostol at home.

Intervention: Misoprostol

Outcomes

Primary Outcomes

Rate of successful abortion

Time Frame: 2 weeks after mifepristone administration

Study Sites (2)

Loading locations...

Similar Trials